Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Group of systemic vasculitis with a strong association with ANCA. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls.
Subtype terms (3)
More specific conditions that are subtypes of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in the MeSH hierarchy.
- Churg-Strauss Syndrome
17 drugs (15 approved, 2 experimental)
- Granulomatosis with Polyangiitis
37 drugs (30 approved, 7 experimental)
- Microscopic Polyangiitis
19 drugs (14 approved, 5 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (5)
Phase 3 trials (8)
Phase 2 trials (13)
Phase 1 trials (16)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (17)
- Bristol-Myers Squibb
- Roche
- ChemoCentryx
- National Institutes of Health (NIH)
- University of Pennsylvania
- Centre Hospitalier Departemental Vendee
- University of Rochester
- University of South Florida
- University of Birmingham
- University of Cambridge
- Leiden University
- University of Freiburg
- University of Lyon
- Institut mutualiste, Paris, France
- University of Paris
- Imperial College London
- Versus Arthritis
Organization Involved with Phase 2 Indications (8)
Organization Involved with Other Experimental Indications (2)